




WHAT IS CLAIMED IS

1. A compound of Formula I:



- 5 or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate ~~or prodrug~~ thereof, wherein:

R^{10} is



or

wherein A, B and D are the same or different and are independently selected from N and C, provided that A, B and D represent at least 1 carbon atom and at most 2 N atoms;

X_1 is selected from O, S or NR^4 ;

X_2 is selected from CH, CR^5 or N;

R^1 is selected from the group consisting of:

- 15 halo,
- C_1 - C_4 alkyl,
- C_2 - C_3 alkenyl,
- C_2 - C_3 alkynyl,
- C_1 - C_4 alkoxy,
- 20 C_1 - C_4 alkylthio,
- phenylthio,
- C_1 - C_4 alkylNH,
- C_1 - C_4 -alkylOC $_1$ - C_4 -alkyl,
- (C_1 - C_4 alkyl) $_2$ N-,
- 25 C_3 - C_6 cycloalkyl,

$\text{NR}^{8a}\text{S}(\text{O})\text{R}^{8a}$, $\text{NR}^{8a}\text{SO}_2\text{R}^{8a}$, $\text{O}(\text{C}=\text{O})\text{NR}^{6a}\text{R}^{7a}$, $\text{O}(\text{C}=\text{O})\text{OR}^{8a}$, $\text{O}(\text{C}=\text{O})\text{R}^{8a}$, $(\text{C}=\text{O})\text{OR}^{8a}$, and 5-6-membered heteroaryl, and

phenyl- C_1 - C_3 -alkyl, wherein the phenyl is substituted by 0 to 5 R^{a5a} groups independently selected from the group consisting of halo, C_1 - C_4 alkoxy, halo- C_1 - C_4 alkoxy, C_1 - C_4 alkyl, halo- C_1 - C_4 alkyl, C_3 - C_6 cycloalkyl, cyano, nitro, $\text{NR}^{6a}\text{R}^{7a}$, OH, C_1 - C_4 -alkylcarbonyloxy- C_1 - C_4 -alkyl, hydroxy- C_1 - C_4 -alkyl, COOR^{8a} , SO_2R^{8a} , $(\text{C}=\text{O})\text{NR}^{6a}\text{R}^{7a}$, $\text{SO}_2\text{NR}^{6a}\text{R}^{7a}$, $\text{N}(\text{R}^{8a})(\text{C}=\text{O})\text{NR}^{6a}\text{R}^{7a}$, $\text{N}(\text{R}^{8a})(\text{C}=\text{O})\text{OR}^{8a}$, $\text{N}(\text{R}^{8a})(\text{C}=\text{O})\text{R}^{8a}$, $\text{NR}^{8a}\text{S}(\text{O})\text{R}^{8a}$, $\text{NR}^{8a}\text{SO}_2\text{R}^{8a}$, $\text{O}(\text{C}=\text{O})\text{NR}^{6a}\text{R}^{7a}$, $\text{O}(\text{C}=\text{O})\text{OR}^{8a}$, $\text{O}(\text{C}=\text{O})\text{R}^{8a}$, $(\text{C}=\text{O})\text{OR}^{8a}$, and 5-6-membered heteroaryl;

R^{b5} is, at each instance, independently selected from the group consisting of:

C_6 - C_{10} aryl substituted by 0 to 3 R^{a1} groups, and

6- to 10-membered heteroaryl substituted by 0 to 3 R^{a1} groups,

R^{6a} and R^{7a} are, at each occurrence, independently selected from the group consisting of:

H,

C_1 - C_6 alkyl, independently substituted with 1 to 5 fluorines, hydroxyl, C_1 - C_4 alkoxy, C_3 - C_6 cycloalkyl, or amino, and

$-(\text{CH}_2)_n$ -phenyl independently substituted with 1 to 3 fluorines, hydroxyl, C_1 - C_4 alkoxy, fluoro- C_1 - C_2 alkoxy, C_3 - C_6 cycloalkyl, or amino, alternatively, R^{6a} and R^{7a} , when attached to the same nitrogen, combine to form a 4- to 6-membered heterocyclic ring containing carbon atoms substituted by 0 to 3 groups independently selected from the group consisting of halo, CF_3 , CHF_2 , OCF_3 , OCHF_2 , OCH_2F , 5- or 6-membered heteroaryl, OH, oxo, hydroxy- C_1 - C_4 -alkyl, C_1 - C_4 alkyl and C_1 - C_4 alkoxy, and 0 to 2 additional heteroatoms selected from N, NR^{13} , O and $\text{S}(\text{O})_p$;

R^{8a} and R^{9a} are, at each occurrence, independently selected from the group consisting of:

H,

C_1 - C_6 alkyl independently substituted with 1 to 5 fluorines, hydroxyl, C_1 - C_4 alkoxy, C_3 - C_6 cycloalkyl, or amino, and

$-(CH_2)_n$ -phenyl independently substituted with 1 to 3 fluorines, hydroxyl, C_1 - C_4 alkoxy, fluoro- C_1 - C_2 alkoxy, C_3 - C_6 cycloalkyl, or amino;

R^c is independently, at each occurrence, selected from the group consisting of H,


5 C_1 - C_6 alkyl, and $-(CH_2)_n$ -phenyl;

n , at each occurrence, is selected from 0, 1, 2, 3 and 4;






p , at each occurrence, is selected from 0, 1 and 2; and


s , at each occurrence, is selected from 0, 1, 2 and 3,

provided that when R^1 is Br, R^{10} is other than unsubstituted



10 and provided that the compound of Formula I is not





wherein said term “4- to 10-membered heterocyclyl” refers to 4- to 10-membered monocyclic, bicyclic or tricyclic heterocyclic ring which is saturated or partially unsaturated and which consists of carbon atoms and 1, 2, 3, or 4 heteroatoms independently selected from the group consisting of N, NH, O and S and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring, and said term “6- to 10-membered heteroaryl” refers to 6-10 membered monocyclic and polycyclic aromatic hydrocarbons that include at least one heteroatom ring member such as sulfur, oxygen, or nitrogen.

2. The compound as defined in Claim 1 wherein:

R^1 is selected from the group consisting of:

halo which is Br or Cl,



methyl,



ethyl,

C_1 - C_2 alkoxy,

cyclopropyl,

CH_3S ,





5


10

15

20

25

30




wherein R^x is CH_3O and R^{3b} is F, or

R^x is OH and R^{3b} is CH_3O , or

R^x is Br and R^{3b} is CH_3O , or

5 R^x is CH_3O and R^{3b} is Br;

(5)



wherein R^{3a} is selected from the group consisting of:

10 $-\text{CH}_3$,


$-\text{OCH}_3$,

NO_2 ,


Cl,

F, and

15



(6)




wherein R^x , R^{3a} , R^{3b} , R^{3c} and R^{3d} are as follows:

20

where R^{3a} is F; and

(5)









5 where

R^x is OCH_3 and R^{3b} is OCH_3 or


R^x is CH_3 and R^{3b} is Cl.

10 12. The compound as defined in Claim 1, wherein the compound is selected from one of the examples, any of claims 1-11 or a compound selected from:








or






5 or a stereoisomer, tautomer, a pharmaceutically acceptable salt or solvate thereof,
alone or in combination with another therapeutic agent.


10 13. A pharmaceutical composition, which comprises a pharmaceutically acceptable
 carrier and a compound as defined in ~~Claim 1~~ any of claims 1 to 11, or a compound selected
from the compounds shown below, or stereoisomers, ~~tautomers,~~ or pharmaceutically acceptable
 salts, ~~or solvates~~ thereof, alone or in combination with another therapeutic agent:-





15








or





14. Use of a therapeutically effective amount of a compound as defined in any of claims 1 to 11, or a compound selected from the compounds shown below ~~Claim 1~~, or stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates thereof in the manufacture of a medicament for the treatment of a thromboembolic disorder or the primary or secondary prophylaxis of a thromboembolic disorder, wherein the thromboembolic disorder is selected from the group consisting of arterial cardiovascular thromboembolic disorders, venous cardiovascular thromboembolic disorders, cerebrovascular thromboembolic disorders, and thromboembolic disorders in the chambers of the heart or in the peripheral circulation;









15. Use of a therapeutically effective amount of a PAR4 antagonist, as defined in Claim 1 any of claims 1 to 11, or a compound selected from the compounds shown below, or stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates thereof, in the manufacture of a medicament for inhibiting or preventing platelet aggregation.



5



or

